BioSpace News Archive

Verona Pharma plc, a clinical-stage biopharmaceutical company focused on respiratory diseases, announces ensifentrine met all safety objectives in a thorough QT study designed to evaluate effects, if any, of ensifentrine on cardiac conduction in healthy individuals.

Nordic Nanovector ASA, a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces the appointment of Sandra Jonsson, PhD, MBA as Chief Operating Officer.

Debiopharm, a Swiss biopharmaceutical company, announced the first patient treated in the newly launched open-label, phase I study evaluating Debio 0123, an oral, potent and highly selective WEE1 inhibitor, as monotherapy in patients with advanced solid tumors.

Antengene Corporation Limited and XtalPi Inc announced today a long-term R&D collaboration.

ZOLL® Medical Corporation announced that it has successfully completed its previously announced acquisition of Itamar™ Medical Ltd., a medical device and digital health company that provides at-home testing for sleep apnea.

Kodiak Sciences Inc. announced that it has completed enrollment in its BEACON Phase 3 clinical trial of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in patients with macular edema due to retinal vein occlusion.

Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, announced that the Company’s presentation at the 40th Annual J.P. Morgan Healthcare Conference has been moved due to the conference moving into a virtual format.

Cullinan Oncology, Inc. today reported updated data from the Company’s ongoing Phase 1/2a trial of CLN-081 in non-small cell lung cancer (NSCLC) patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 20 insertion mutations that have progressed on or after prior therapy.

Century Therapeutics today announced updated preclinical data from the Company’s CNTY-101 program and CAR-iT platform.

ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced the first patients dosed in Phase 2/3 Sirius and Celeste clinical trials of investigational RNA therapy QR-421a for people with USH2A mediated retinitis pigmentosa (RP) and Usher syndrome.